Skip to search formSkip to main contentSkip to account menu

Linagliptin

Known as: 1H-purine-2,6-dione, 8-((3r)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-, (R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione, Linagliptin [Chemical/Ingredient] 
A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP… 
National Institutes of Health

Related topics

Related topics

25 relations
24 HR Linagliptin 5 MG / Metformin hydrochloride 1000 MG Extended Release Oral TabletDipeptidyl Peptidase 4 Inhibitors [MoA]In BloodIndigo Carmine

Narrower (3)

BI 1356GlyxambiTradjenta

Broader (3)

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsIncretins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin
Background In addition to lowering blood glucose in patients with type 2 diabetes mellitus, dipeptidyl peptidase 4 (DPP4… 
2012
2012
Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A₂B adenosine receptor antagonists.
Molecular modeling studies, including the comparative molecular field analysis (CoMFA) method, on 52 antagonists of the A(2B… 
Review
2012
Review
2012
Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
  • B. Gallwitz
  • Clinical Medicine Insights: Endocrinology and…
  • 2012
  • Corpus ID: 9873529
Incretin based therapies have been introduced into the treatment options of type 2 diabetes a few years ago. Among them, the… 
2011
2011
The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.
AIM To evaluate the potential effects of therapeutic and supratherapeutic doses of linagliptin (BI 1356) on the QT/QT(c) interval… 
2010
2010
Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin.
OBJECTIVE This study was conducted to investigate any potential effect of the dipeptidyl peptidase-4 inhibitor linagliptin (which… 
2010
2010
Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5mg–10mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in…
Background and ObjectivesLinagliptin (BI 1356) is a highly specific inhibitor of dipeptidyl peptidase (DPP)-4, which is currently… 
2010
2010
Chronic administration of DSP‐7238, a novel, potent, specific and substrate‐selective DPP IV inhibitor, improves glycaemic control and β‐cell damage in diabetic mice
Aims: The purpose of this study is to assess the in vitro enzyme inhibition profile of DSP‐7238, a novel non‐cyanopyrrolidine… 
Highly Cited
2009
Highly Cited
2009
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
ABSTRACT Objective: Linagliptin (BI 1356) is a novel, orally available inhibitor of dipeptidyl peptidase-4 (DPP-4). Linagliptin… 
Review
2009
Review
2009
Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Boehringer Ingelheim Corp is developing the novel, xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor linagliptin for the… 
2006
2006
Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonists.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)